3-methoxy-6-keto-normorphinan | 4978-44-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 3-methoxy-6-keto-normorphinan
• 英文别名: 3-methoxymorphinan-6-one；(1S,9R,10R)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
• CAS: 4978-44-3
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: YQDNOFJTUBTARC-UAGQMJEPSA-N

物化性质

• 沸点：
  449.6±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methoxy-6-keto-normorphinan 在 氢溴酸 、 溴 、 碳酸氢钠 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 (1S,9R,10R)-20-(cyclobutylmethyl)-15-methoxy-6-thia-4,20-diazapentacyclo[8.7.3.01,9.03,7.012,17]icosa-3(7),4,12(17),13,15-pentaen-5-amine
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of 6,7-Indolo/Thiazolo-MorphinansFurther SAR of Levorphanol

  摘要：

  To further extend the structure-activity relationships of levorphanol, two series of novel morphinans were prepared by incorporation of an indole or aminothiazole fragment to the hexyl ring (ring C) in levorphanol. Such morphinans differed from previously reported ligands in that such indole- or aminothiazole-containing morphinans displayed enhanced binding affinity to the delta opioid receptor, while the affinity to kappa and mu receptors was slightly reduced.

  DOI：

  10.1021/jm0701674
• 作为产物：
  描述：

  二氢可待因酮 在 吡啶 、 盐酸 、 氨 、 sodium 、 氯甲酸乙酯 、 铜 、 potassium carbonate 、 caesium carbonate 、 对甲苯磺酸 、 溶剂黄146 、 锌 作用下， 以 氯仿 、 甲苯 、 苯 为溶剂， 反应 63.0h， 生成 3-methoxy-6-keto-normorphinan
  参考文献：
  名称：

  Synthesis and Pharmacological Evaluation of 6,7-Indolo/Thiazolo-MorphinansFurther SAR of Levorphanol

  摘要：

  To further extend the structure-activity relationships of levorphanol, two series of novel morphinans were prepared by incorporation of an indole or aminothiazole fragment to the hexyl ring (ring C) in levorphanol. Such morphinans differed from previously reported ligands in that such indole- or aminothiazole-containing morphinans displayed enhanced binding affinity to the delta opioid receptor, while the affinity to kappa and mu receptors was slightly reduced.

  DOI：

  10.1021/jm0701674

文献信息

• [EN] MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] DÉRIVÉS DE MORPHINANE POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2016182840A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.

  本发明涉及化合物及其用作阿片μ受体的配体的应用。还包括制备这些化合物的方法和包含这些化合物的药物组合物。在发明的至少一个实施例中，提供了一种根据公式I的化合物：及其药用可接受的盐，其中R1-R11如本文所述。
• 17-Cycloalkylmethyl-6-methylene-morphinane-derivatives
  申请人：MILES LABORATORIES, INC.

  公开号：EP0027925A1

  公开（公告）日：1981-05-06

  Disclosed are 6-methylene, morphinan compounds corresponding to the formula: wherein R1 und R3 are H or methyl and R2 is cyclopropylmethyl or cyclobutylmethyl. These compounds are useful as mixed analgesics/narcotic antagonists.

  所公开的 6-亚甲基吗啡烷化合物符合以下式子： 其中 R1 和 R3 为 H 或甲基，R2 为环丙基甲基或环丁基甲基。这些化合物可用作混合镇痛剂/麻醉拮抗剂。
• Morphinan derivatives for the treatment of neuropathic pain
  申请人：Nektar Therapeutics

  公开号：US10766864B2

  公开（公告）日：2020-09-08

  The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.

  本发明涉及化合物及其作为μ阿片受体配体的用途。还包括制备这些化合物的方法和含有这些化合物的药物组合物。在本发明的一个或多个实施方案中，提供了根据式 I 的化合物：及其药学上可接受的盐，其中 R1-R11 如本文所述。
• Design and synthesis of novel delta opioid receptor agonists and their pharmacologies
  作者：Hiroshi Nagase、Yumiko Osa、Toru Nemoto、Hideaki Fujii、Masayuki Imai、Takashi Nakamura、Toshiyuki Kanemasa、Akira Kato、Hiroaki Gouda、Shuichi Hirono

  DOI：10.1016/j.bmcl.2009.03.099

  日期：2009.5

  We re-examined the accessory site of the 4,5-epoxymorphinan skeleton by CAMDAS conformational analysis in an effort to deign novel delta opioid receptor antagonists. We synthesized three novel compounds (SN-11, 23 and 28) with a 10-methylene bridge and without a 4,5-epoxy ring. Among them, compounds SN-23 (17-isobutyl derivative) and SN-28 (17-methyl derivative) showed very strong agonist activity (over 10 times more than TAN-67). SN-28 also showed high delta selectivity. The delta agonist activity of SN-23 was weaker than that of SN-28, but in terms of the delta selectivity, SN-23 was higher than that of SN-28. These unexpected results indicated that the 4,5-epoxy ring, but not the 10-methylene bridge, was an accessory site in delta opioid receptor agonists. (C) 2009 Elsevier Ltd. All rights reserved.
• MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN
  申请人：Nektar Therapeutics

  公开号：EP3294714A1

  公开（公告）日：2018-03-21